Lymphoid Interstitial Pneumonitis - Symptoms, Diagnosis, and Treatment

Introduction

Lymphoid interstitial pneumonia (LIP) is a rare form of interstitial lung disease in adults that is histopathologically defined by lymphocytes, plasma cells, and additional lymphoreticular elements infiltrating the lung's interstitium and alveolar spaces. Carrington and Liebow first described LIP in 1966, one of several lymphoproliferative diseases that can affect the lungs.

Many patients previously identified as LIP are now classified as cellular nonspecific interstitial pneumonia (NSIP). The reason is unknown. Symptoms and indications include coughing, increasing dyspnea, and crackling. The diagnosis is based on a history, a physical examination, imaging studies, and a lung sample. Corticosteroids, cytotoxic medicines, or both are used to treat the condition, but their usefulness is unknown. The prognosis is primarily unclear and based on case studies.

What Is Lymphoid Interstitial Pneumonitis?

Lymphocytic interstitial pneumonia is an uncommon idiopathic interstitial pneumonia characterized by tiny lymphocyte infiltration of the alveoli and alveolar septa, as well as varied amounts of plasma cells. Non-necrotizing, weakly formed granulomas may be present, but they are usually uncommon and inconspicuous. The cause is thought to be an autoimmune disease or a nonspecific reaction to infection with Epstein-Barr virus, AIDS, or other viruses. The frequent relationship between Sjogren syndrome and other illnesses suggests an autoimmune etiology.

LIP is the most prevalent form of pulmonary disease in HIV-positive children after pneumocystis infection. It is the AIDS-defining condition in pneumocystis infection, and it is the AIDS-defining condition in up to half of them. LIP affects less than 1 percent of adults, either with or without HIV infection. Women and girls suffer more frequently. Evidence of an indirect viral origin includes an expected correlation with immunodeficient states and Epstein-Barr virus DNA and HIV RNA in the lung tissue of LIP patients. This idea proposes that LIP is a severe expression of the normal capacity of lymphoid tissue in the lung to react to inhaled and circulating antigens.

What Are the Symptoms of Lymphocytic Interstitial Pneumonitis?

Adults with lymphocytic interstitial pneumonia develop increasing dyspnea and coughing. These manifestations develop over months or, in certain instances, even years and emerge at an average age of 54. Weight loss, a high temperature, arthralgias, and night sweats are uncommon. Cracks may be discovered during an examination. Hepatosplenomegaly, osteoarthritis, and lymphadenopathy are unusual findings that indicate a secondary or alternative diagnosis. If the condition advances to end-stage respiratory failure, cyanosis and clubbing may occur. Hypertrophy of the salivary glands may be detected in 20 % of patients.

What Are the Radiographic Features of Lymphocytic Interstitial Pneumonitis?

Features can be non-specific and may include:

• Lower-zone dominant bilateral reticular opacification.

• Chronic bilateral airspace opacification.

Scattered thin-walled perivascular cysts are common in Sjogren's syndrome, but they are more likely the result of multifocal lung damage by macrophage metalloproteinases rather than LIP. Unfortunately, current classifications still include cysts as a characteristic of 'radiological' LIP, as opposed to pathological LIP, which does not contain cysts. Macrophages are drawn to areas of protein deposition, and the thin-walled cysts may contain interior strands similar to those seen in light chain deposition illness and other lymphoplasmacytic disorders.

The following features may be found with lymphoid interstitial pneumonia on HRCT, although the findings are not exclusive to this diagnosis:

• Small, variable-sized pulmonary nodules.

• Ground-glass changes.

• Mediastinal lymphadenopathy.

• The traits tend to be widespread, with mid- to lower-lobe predominance.

• The thickening of bronchovascular bundles.

• Interstitial thickening along lymphatic channels.

How Is Lymphocytic Interstitial Pneumonitis Diagnosed?

Lymphocytic interstitial pneumonia is typically suspected in at-risk patients who exhibit compatible symptoms. Imaging tests and, on occasion, a lung biopsy are performed.

1. Lung Biopsy: Adults require a lung biopsy to diagnose lymphocytic and additional immune cell infiltrates that have expanded the alveolar septae. Infiltrates occur occasionally throughout the bronchi and arteries but are most common along the alveolar septa. The tissue must be stained with immunohistochemistry and analyzed using flow cytometry to identify LIP from primary lymphomas. The infiltrate in LIP is polyclonal, whereas infiltrates in other lymphomas are monoclonal. Other common features include germinal centers, multinucleated giant cells, and noncaseating granulomas.

2. X-ray: A chest X-ray reveals bibasilar linear reticular or nodular opacities, a generic feature in various lung illnesses. More severe illnesses may include alveolar opaque areas, cysts, or both. Bronchoalveolar lavage ought to be performed to rule out infection and may show an increase in lymphocytes.

3. HRCT: HRCT (high-resolution computed tomography) of the chest is performed to determine the extent of the disease, describe hilar anatomy, and identify pleural involvement. HRCT results are quite varied. Centrilobular and subpleural nodules, enlarged bronchovascular bundles, nodular ground-glass opaque areas, and cystic formations are also common observations.

4. Routine Laboratory Tests: Routine laboratory tests and serum protein electrophoresis (SPEP) are performed since around 80 % of patients have a serum protein anomaly, most often polyclonal gammopathy and hypogammaglobulinemia, the significance of which is unknown. Other laboratory tests are used to determine potential causes of secondary LIP.

What is the Prognosis of Lymphocytic Interstitial Pneumonitis?

The natural history and prognosis of LIP in adults are not well characterized. Spontaneous resolution, resolution following corticosteroid or other immunosuppressive drug treatment, lymphoma progression, or the development of pulmonary fibrosis along with respiratory failure are all possible outcomes. The five-year survival rate is 50 to 66 %. Infection, malignant lymphoma, and increasing fibrosis are among the leading causes of death.

How Is Lymphocytic Interstitial Pneumonitis Treated?

The natural history varies, from near-complete remission to persistent disease. Corticosteroids, cytotoxic medicines, or both are used to treat lymphocytic interstitial pneumonia, but the efficacy of this treatment, like that of many other causes of interstitial lung illness, is uncertain. More than 30 percent of individuals will progress to end-stage illness and honeycombing despite treatment. According to specific research, 5-year death rates might vary from 33 to 50 percent. Lymphoma can develop, especially in patients with monoclonal gammopathy or hypogammaglobulinemia.

Conclusion

Lymphocytic interstitial pneumonia, classified as both a lymphoproliferative condition and an interstitial pneumonia, is distinguished by a diffuse, polyclonal lymphoid cell infiltrate encircling the airways and spreading into the lung interstitium. LIP's natural history is diverse, beginning with a benign course and progressing to lymphoma.